-+ 0.00%
-+ 0.00%
-+ 0.00%

Corbus reports 42.9% response rate for CRB-701 in Phase 1/2 second-line oropharyngeal cancer study

PUBT·05/26/2026 11:04:49
Listen to the news
Corbus reports 42.9% response rate for CRB-701 in Phase 1/2 second-line oropharyngeal cancer study
  • Corbus reported updated Phase 1/2 data for Nectin-4 ADC CRB-701 in second-line oropharyngeal cancer, cervical cancer.
  • Results will be presented at the 2026 ASCO meeting.
  • Study showed meaningful tumor shrinkage in both cancers, supporting a path toward late-stage development in HPV-driven disease.
  • Safety profile remained broadly manageable, with low treatment discontinuations despite frequent eye-related side effects.
  • Registrational TEMPO-1 trial in second-line oropharyngeal cancer remains on track to start in summer 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.